Vendor Intelligence Report: Uther

Executive summary

Across 86 Finnrick lab tests, Uther records 64 pass and 22 fail, a 74% overall pass rate. The useful read is uneven, not binary: GHK-Cu and Tirzepatide are the stronger signals in the current set, while Survodutide and CJC-1295 are the names that should push buyers toward another source or exact-lot testing. Uther's ratings also compress under stricter Finnrick methodologies, so the public score is only the entry point.

The provenance file is more concerning than a simple pass-rate chart. Uther's legacy China-hosted identity presented a large Hunan pharmaceutical manufacturer; the strongest third-party trade-platform record points to a much smaller Hainan trading/e-commerce footprint. The report also maps a fast 2025 UK company layer, including a dissolved Uther entity, an active Uther wrapper, and a same-director/same-address connection to Reta Labs X, a related site selling pre-filled retatrutide and GHK-Cu pens.

Product-risk is also bifurcated. The NAD+ record sits outside the Finnrick peptide table but is the highest-severity safety signal, with community testing showing a multi-batch endotoxin-failure pattern. Tirzepatide remains one of Uther's better Finnrick products, yet a disputed T60 zero-detection incident keeps batch identity and independent verification relevant. Add crypto-forward payment rails and documented Telegram/Reddit impersonation, and Uther becomes a vendor where channel verification matters almost as much as peptide selection.

Inside the full report:

• Per-product pass/fail rates, rating trajectories, and methodology-divergence charts for all 13 Finnrick-tested products
• Wayback, Made-in-China, DNS, and domain records comparing the historical manufacturer story with the verified trading-profile footprint
• Companies House filings for the dissolved Uther entity, the active UK wrapper, and the Reta Labs X shared-director/address link
• Community-testing evidence on NAD+ endotoxin failures and the disputed Tirzepatide T60 zero-detection episode
• Telegram, Reddit, and GLP-1 Forum artifacts documenting impersonation channels and buyer-authentication risk
• Payment-route analysis covering Simplex card-to-crypto, ACH, direct crypto, and practical refund exposure

Risk assessment

• Corporate-identity and transparency risk — high: Verified trade listing is a two-employee Haikou e-commerce/trading firm, while historic Uther pages claimed a 2007 Hunan pharmaceutical manufacturer with 100+ employees and copied China Resources text.
• Product-specific Finnrick quality risk: Survodutide, CJC-1295, Tesamorelin and Cagrilintide — high: Finnrick flags weak product-specific performance: Survodutide 42.31% with 1 pass/3 fail, CJC-1295 44.12%, Tesamorelin 52.29% and Cagrilintide 53.89%; do not generalize this to stronger Uther products.
• NAD+ endotoxin-contamination risk — high: Crispy Testing Group/GLP-1 Forum record reported 8 of 11 testable Uther NAD+ 500mg batches failing endotoxin, with visible readings from 564 to 1,251 EU/vial.
• Payment-recourse risk — high: Utherpeptide.com promotes Simplex card-to-crypto, ACH and direct crypto, materially reducing ordinary card chargeback and buyer-refund recourse.
• Copycat and brand-confusion risk — high: Fake Telegram/Reddit scams are documented and reviewed materials did not show robust official-channel, authorized-reseller, signed-COA or anti-counterfeit verification controls.
• Related consumer-injectable regulatory risk — medium: Records indicate UTHER PHARMACEUTICAL LTD and RETA LABS X LTD share a director/address; Reta Labs X sells pre-filled retatrutide and GHK-Cu pens despite research-use framing.